• Revenue of $390.4 million, up by 63% and on track to meet full year guidance
• Group gross profit margin of 53% reflects product mix change to include third-party RLS sales
• $81.6 million invested into R&D, a 47% increase year-over-year

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) today announces its financial results for the half-year ended 30 June 2025. The company reported revenue of $390.4 million, up by 63% compared to the same period in 2024, and on track to meet its full year guidance of $770 million to $800 million. The group's gross profit margin was 53%, reflecting a change in product mix to include third-party RLS sales, while Illuccix's margin remained stable at 64%. Telix invested $81.6 million into R&D, a 47% increase year-over-year, primarily focused on late-stage assets in the therapeutics and precision medicine pipeline. The company reported a loss before tax of $4.8 million, which included $12.4 million in non-cash finance costs and increased amortization costs following the RLS acquisition. Telix's Precision Medicine segment delivered 30% revenue growth, driven by continued increase in Illuccix dose volumes, while the Telix Manufacturing Solutions (TMS) segment saw investment in infrastructure to scale operations and meet future demand. The company's Therapeutics segment reinvested earnings to accelerate the development of its late-stage pipeline, with key milestones achieved in clinical trials for TLX591, TLX592, TLX101, and TLX090.

Telix confirms FY 2025 revenue guidance of US$770 million to US$800 million, reflecting revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS. Telix also confirms R&D expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024.